Crossmark

Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease

Crossref DOI link: https://doi.org/10.1038/s41409-018-0364-5

Published Online: 2018-10-24

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Danylesko, Ivetta

Bukauskas, Adomas

Paulson, Martin

Peceliunas, Valdas

Gedde-Dahl d.y, Tobias

Shimoni, Avichai

Shouval, Roni

Griskevicius, Laimonas

Floisand, Yngvar

Nagler, Arnon
Funding

Funding for this research was provided by:

No
License Information

Text and Data Mining valid from 2018-10-24
More Information

Article History

Received: 14 April 2018

Revised: 15 August 2018

Accepted: 14 September 2018

First Online: 24 October 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.